We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

84 hedge funds and large institutions have $109M invested in Acumen Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

158% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 12

44% more capital invested

Capital invested by funds: $75.2M → $109M (+$33.3M)

18% more funds holding

Funds holding: 71 → 84 (+13)

4.83% more ownership

Funds ownership: 58.87% → 63.7% (+4.8%)

31% less call options, than puts

Call options by funds: $246K | Put options by funds: $355K

Holders
84
Holders Change
+13
Holders Change %
+18.31%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
31
Reduced
12
Closed
7
Calls
$246K
Puts
$355K
Net Calls
-$109K
Net Calls Change
-$179K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$15.5M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.86M
3
ACM
ADAR1 Capital Management
Texas
+$3.23M
4
IC
Ikarian Capital
Texas
+$2.04M
5
Two Sigma Investments
Two Sigma Investments
New York
+$989K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.22M
2
Citadel Advisors
Citadel Advisors
Florida
-$881K
3
LCM
Laurion Capital Management
New York
-$871K
4
Jane Street
Jane Street
New York
-$134K
5
XT
XTX Topco
Cayman Islands
-$105K
Name Holding Trade Value Shares
Change 		Change in
Stake
SS
76
SBI Securities
Japan
$715 -$51 -20 -6%
FFA
77
Farther Finance Advisors
California
$510 – – –
NB
78
NBT Bank
New York
$472 +$505 +198 +9,900%
TRCT
79
Tower Research Capital (TRC)
New York
$278 -$11.1K -4,339 -97%
Carson Wealth (CWM LLC)
80
Carson Wealth (CWM LLC)
Nebraska
$205 -$153 -60 -41%
CA
81
Clearstead Advisors
Ohio
$142 – – –
AAP
82
Arax Advisory Partners
Colorado
$61 – – –
LFG
83
Larson Financial Group
Missouri
$47 -$11K -4,328 -100%
Optiver Holding
84
Optiver Holding
Netherlands
$12 – – –
Two Sigma Advisers
85
Two Sigma Advisers
New York
– -$890K -421,800 Closed
Citadel Advisors
86
Citadel Advisors
Florida
– -$881K -345,283 Closed
XT
87
XTX Topco
Cayman Islands
– -$105K -49,563 Closed
QC
88
Quadrature Capital
United Kingdom
– -$103K -49,046 Closed
VF
89
Virtu Financial
New York
– -$23K -10,922 Closed
NMC
90
Nine Masts Capital
Hong Kong
– -$22.4K -10,637 Closed
FHA
91
Flagship Harbor Advisors
Massachusetts
– -$739 -350 Closed
1 2 3
4

ABOS Hedge Fund Activity: Q1 2026 in Review

84 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2026, worth a combined $109M — up 44% from $75.2M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABOS positions and 7 closed out — a net gain of 14 holders — while 31 added to existing stakes and 12 trimmed.

The largest buyer was RA Capital Management, adding an estimated $15.5M. The largest seller was Fidelity Investments, cutting an estimated $2.22M.

  • 84 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2026, up from 71 in Q4 2025.
  • Funds reported $109M of Acumen Pharmaceuticals stock for Q1 2026, up 44% quarter-over-quarter.
  • 21 funds opened new Acumen Pharmaceuticals positions in Q1 2026 and 7 closed out, a net change of +14 holders.
  • The largest Acumen Pharmaceuticals buyer in Q1 2026 was RA Capital Management, an estimated $15.5M added.
  • The largest Acumen Pharmaceuticals seller in Q1 2026 was Fidelity Investments, an estimated $2.22M sold.

Based on aggregated 13F filings for Q1 2026.